Last year after the ASCO meeting in Chicago I declared that there was one particular presentation of the CHAARTED trial that would be a game changer for the treatment of newly diagnosed men with very significant prostate cancer. The game changer was that men diagnosed with significant disease and who were still ADT naive (not yet had any hormone therapy) would have their life extended if they had a short course (six sessions) of chemotherapy despite their still being hormone sensitive.

As happens in scientific research this finding was contradicted at one of last month’s plenary session at ASCO GU. At the session Dr. Gwenaelle Gravis, MD, PhD from the Department of Medical Oncology, Institute Paoli Calmettes in France reported on the long-term results of the phase III androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for ho